Results 181 to 190 of about 14,850 (194)

Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial

Circulation, 2022
Remo Holanda de Mendonça Furtado, Itamar Raz, Erica L Goodrich   +2 more
exaly  

Dapagliflozin in Patients with Chronic Kidney Disease

New England Journal of Medicine, 2020
Bergur V Stefansson, Ricardo C Correa-Rotter, Glenn Chertow   +2 more
exaly  

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age

Circulation, 2020
Chern-En Chiang, Sergey Tereshchenko, Lars Køber   +2 more
exaly  

Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial

Lancet, The, 2023
exaly  

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

New England Journal of Medicine, 2022
John J V Mcmurray, Rudolf A De Boer, Muthiah Vaduganathan   +2 more
exaly  

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Lancet, The, 2010
Clifford J Bailey
exaly  

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

New England Journal of Medicine, 2019
John J V Mcmurray, Lars Køber, Mikhail N Kosiborod   +2 more
exaly  

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

Circulation, 2020
Inder S Anand, Rudolf A De Boer, Michael Böhm   +2 more
exaly  

Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium

Pharmacological Research, 2020
Antonella De Angelis, Raffaele Coppini, Carmela Dell'aversana   +2 more
exaly  

Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58

Circulation, 2020
Marc P Bonaca, Stephen Wiviott, Ofri Mosenzon   +2 more
exaly